While Denali Therapeutics Inc has underperformed by -3.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DNLI fell by -30.47%, with highs and lows ranging from $33.33 to $10.57, whereas the simple moving average fell by -27.77% in the last 200 days.
On April 10, 2025, Cantor Fitzgerald Upgraded Denali Therapeutics Inc (NASDAQ: DNLI) to Overweight. Deutsche Bank also rated DNLI shares as ‘Buy’, setting a target price of $31 on the company’s shares in an initiating report dated February 11, 2025. Robert W. Baird Initiated an Outperform rating on January 07, 2025, and assigned a price target of $31. William Blair initiated its ‘Outperform’ rating for DNLI, as published in its report on January 03, 2025. Stifel’s report from December 16, 2024 suggests a price prediction of $37 for DNLI shares, giving the stock a ‘Buy’ rating. Raymond James also rated the stock as ‘Mkt Perform’.
Analysis of Denali Therapeutics Inc (DNLI)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Denali Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -35.21% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.56, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and DNLI is recording an average volume of 1.47M. On a monthly basis, the volatility of the stock is set at 4.78%, whereas on a weekly basis, it is put at 5.23%, with a loss of -1.12% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.33, showing growth from the present price of $14.17, which can serve as yet another indication of whether DNLI is worth investing in or should be passed over.
How Do You Analyze Denali Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 13.46%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.26% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
DNLI shares are owned by institutional investors to the tune of 92.26% at present.
